Carfilzomib公司
蛋白酶体抑制剂
硼替佐米
多发性骨髓瘤
达拉图穆马
药理学
癌症研究
医学
化学
内科学
作者
Ran Chen,Jiakun Yang,Yumin Mao,Xiaofei Zhao,Ru Cheng,Chao Deng,Zhiyuan Zhong
出处
期刊:Biomacromolecules
[American Chemical Society]
日期:2023-10-06
卷期号:24 (11): 5371-5380
被引量:6
标识
DOI:10.1021/acs.biomac.3c00830
摘要
-PMs-CFZ revealed little toxic effects and effectively prevented osteolytic lesions. The antibody-targeted nanodelivery of a proteasome inhibitor appears to be an appealing strategy to treat multiple myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI